Trial Profile
A retrospective study evaluating the rate of QTcP and associated risk factors in hemato-oncologic patients treated with voriconazole
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Sep 2017
Price :
$35
*
At a glance
- Drugs Voriconazole (Primary)
- Indications Candidiasis
- Focus Adverse reactions
- 26 Sep 2017 New trial record
- 01 Sep 2017 Results published in the European Journal of Clinical Pharmacology